Assessment of Pfmdr1 and Pfcrt Mutations After Six Years of Implementation of Artemisinin-Based Combination Therapy in Dakar Senegal.

Background: Artemisinin-based combination therapies (ACTs) have been shown to be effective for uncomplicated P. falciparum malaria in Africa including Senegal. In South East Asia, Pfmdr1 Single Nucleotide Polymorphism (SNPs) are frequent and tentatively associated with reduced susceptibility to ACT partner drugs mefloquine and lumefantrine. In Africa where amodiaquine is one the most partner drugs of ACT, studies on molecular marker of AQ resistance are urgent. The objective of this study is to monitor molecular markers of AQ the partner drug of ACT in Senegal.